PARP inhibitor

Results: 49



#Item
1Dries 1 Annika Dries Human Biology 158G Final Project 6 December 2013 The PARP inhibitor: the promises and challenges of targeted breast cancer therapy

Dries 1 Annika Dries Human Biology 158G Final Project 6 December 2013 The PARP inhibitor: the promises and challenges of targeted breast cancer therapy

Add to Reading List

Source URL: biochem158.stanford.edu

Language: English - Date: 2013-12-15 18:24:45
    2Theranostics 2016, Vol. 6, IssueIvyspring

    Theranostics 2016, Vol. 6, IssueIvyspring

    Add to Reading List

    Source URL: www.thno.org

    Language: English - Date: 2016-07-16 08:44:18
    3The DNA damage response in tumorigenesis and cancer treatment Jiri Bartek and Jiri Lukas The cellular DNA damage response (DDR) machinery is intimately linked with cancer as damage to DNA causes cancer. The DDR provides

    The DNA damage response in tumorigenesis and cancer treatment Jiri Bartek and Jiri Lukas The cellular DNA damage response (DDR) machinery is intimately linked with cancer as damage to DNA causes cancer. The DDR provides

    Add to Reading List

    Source URL: inflacare.imbb.forth.gr

    Language: English - Date: 2011-04-18 10:08:09
    4Final results of the phase I first-in-man trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carri

    Final results of the phase I first-in-man trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carri

    Add to Reading List

    Source URL: www.tesarobio.com

    Language: English - Date: 2013-06-03 17:45:31
      5Microsoft Word - BeiGene BGB 290 FPI Release_Final

      Microsoft Word - BeiGene BGB 290 FPI Release_Final

      Add to Reading List

      Source URL: www.beigene.com

      Language: English
      6ARIEL2: A phase 2 study to prospectively identify ovarian cancer patients likely to respond to rucaparib Elizabeth Swisher,1 James Brenton,2 Scott Kaufmann,3 Amit Oza,4 Robert L. Coleman,5 David O’Malley,6 Gottfried Ko

      ARIEL2: A phase 2 study to prospectively identify ovarian cancer patients likely to respond to rucaparib Elizabeth Swisher,1 James Brenton,2 Scott Kaufmann,3 Amit Oza,4 Robert L. Coleman,5 David O’Malley,6 Gottfried Ko

      Add to Reading List

      Source URL: www.foundationmedicine.com

      Language: English - Date: 2014-11-25 16:41:42
      7Nationwide Study of Breast Cancer Risk Factors in Latinas Michael Dean, Latoya Silverton, Julie Sawitzke Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute

      Nationwide Study of Breast Cancer Risk Factors in Latinas Michael Dean, Latoya Silverton, Julie Sawitzke Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute

      Add to Reading List

      Source URL: precedings.nature.com

      Language: English
      8Ovarian cancer / Tumor antigen / Breast cancer / BRCA1 / PARP inhibitor / CA-125 / Cancer / Medicine / Oncology / Gynaecological cancer

      LIST OF ABSTRACTS GENETICS AND GENOMICS Stefan Bentink, Renee Rubio, Eleanor Howe, Craig April, Jing Chen, Jian-Bing Fan, Kristina Holton, Joyce Liu, Michelle Hirsch, Ursula Matulonis, and John Quackenbush

      Add to Reading List

      Source URL: www.dfhcc.harvard.edu

      Language: English - Date: 2011-08-31 17:02:34
      9

      PDF Document

      Add to Reading List

      Source URL: f1000.com

      Language: English
      10Turner and Tutt Breast Cancer Research 2012, 14:115 http://breast-cancer-research.com/contentE D I TO R I A L  Platinum chemotherapy for BRCA1-related breast

      Turner and Tutt Breast Cancer Research 2012, 14:115 http://breast-cancer-research.com/contentE D I TO R I A L Platinum chemotherapy for BRCA1-related breast

      Add to Reading List

      Source URL: breast-cancer-research.com

      Language: English